Ultragenyx Pharmaceutical Inc (RARE) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ultragenyx Pharmaceutical Inc   (NASDAQ: RARE)

Ultragenyx Pharmaceutical Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Ultragenyx Pharmaceutical Inc in the third quarter 2026?
Due to the lack of equity, it was not possible to calculate Ultragenyx Pharmaceutical Inc 's return on equity (ROE) in its third quarter 2026

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -524 -586 -609 -575 -580
Return On Equity (TTM) - - - -1023.63 % -414.17 %
RARE's Total Ranking # # # # #
Equity (TTM) in Millions -376 -291 -236 -80 9
Seq. Equity Change - - - - -93.95 %
Seq. Net Income Change - - - - -

Back to RARE Management Effectiveness >> RARE's 5 Years Annual ROE >> Compare RARE ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





RARE Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions -80 255 275 352 923
Y / Y Equity Change - -7.3 % -21.87 % -61.79 % -20.08 %
Net Income in Millions -575 -569 -607 -707 -454
Y / Y Net Income Change - - - - -
Return On Equity - -222.95 % -220.26 % -200.69 % -49.21 %

Back to RARE Management Effectiveness >> RARE's 5 Years Annual ROE >> Compare RARE ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RARE's' Return on Equity at Yahoo Finance
RARE's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RARE's Competitors
Subscribers only: Roe for Ultragenyx Pharmaceutical Inc 's Suppliers
Subscribers only: Return On Equity for RARE's Customers




Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector ROE
Alnylam Pharmaceuticals Inc   159.72 %
Medpace Holdings Inc   99.76 %
3m Company  93.07 %
Exelixis Inc   85.83 %
Eli Lilly And Company  83.65 %
Idexx Laboratories Inc  71.18 %
Tenet Healthcare Corp  57.13 %
Aurinia Pharmaceuticals Inc   51.92 %
Nurix Therapeutics Inc   49.34 %
Carlisle Companies Incorporated  44.18 %
Bristol myers Squibb Company  43.83 %

Date modified: 2026-11-05T13:25:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.